alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 63 studies by Aarsland D (page 2 of 3) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 63 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2007-03-01

For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Risk of dementia in Parkinson's disease: a community-based, prospective study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 2001-03-01

Forty-three patients with PD were demented at follow-up evaluation, equivalent to an incidence rate of 95.3 per 1,000 person-years (95% CI, 68.2 to 122.0). 2 key findings →

Participants: 171 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Movement disorders : official journal of the Movement Disorder Society 2007-12-01

A preceding article described the clinical features of Parkinson's disease dementia (PD-D) and proposed clinical diagnostic criteria for "probable" and "possible" PD-D. The main focus of this article is to operationalize the diagnosis of PD-D and to propose practical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of neurology, neurosurgery, and psychiatry 2009-11-01

Apathy is a persistent behavioural feature in PD with a high incidence and prevalence over time. 3 key findings →

Design: longitudinal study Participants: 139 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Neurology 2008-11-19

The findings demonstrate a twofold increase in the proportion with cognitive impairment in subjects with early, untreated Parkinson disease (PD) compared to controls. 4 key findings →

Participants: 196 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment

✓ Peer-reviewed alzhub usefulness score 54 out of 100. The Lancet. Neurology 2012-08-01

Dementia is one of the most common and important aspects of Parkinson's disease and has consequences for patients and caregivers, and has health-related costs. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Mild cognitive impairment: the Manchester consensus

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Age and ageing 2021-01-01

Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01

Our results suggest that risperidone may affect the CSF profile of AD biomarkers indicating more amyloid pathology. 5 key findings →

Participants: 44 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Movement disorders : official journal of the Movement Disorder Society 2006-09-01

The aim of this study was to establish the rate of progression from mild cognitive impairment (MCI) to dementia in patients with Parkinson's disease (PD). 3 key findings →

Participants: 34 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Movement disorders : official journal of the Movement Disorder Society 2015-03-04

Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The prognosis of dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Lancet. Neurology 2017-03-22

Dementia with Lewy bodies is the second most common form of neurodegenerative dementia, yet scarce evidence is available about its prognosis and natural history, which are crucial to inform clinical practice and research. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Validity and Cultural Generalisability of a 5-Minute AI-Based, Computerised Cognitive Assessment in Mild Cognitive Impairment and Alzheimer's Dementia

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Frontiers in psychiatry 2021-07-22

The ICA demonstrated convergent validity with MoCA (Pearson r=0.58, p<0.0001) and ACE (r=0.62, p<0.0001). 5 key findings →

Participants: 230 Evidence: low

Full summary, score breakdown and related studies → Original source

Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of Parkinson's disease 2015-01-01

The association between reduced CSF α-synuclein concentrations and cognition suggests that α-synuclein pathology contributes to early cognitive impairment in PD, in particular to executive-attentional dysfunction. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurology 2007-08-01

We found that despite a similar severity of dementia, patients with dementia with Lewy bodies (DLB) had more cortical atrophy than patients with Parkinson disease with dementia (PDD), indicating different brain substrates underlying dementia in the two syndromes. 5 key findings →

Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Dementia and geriatric cognitive disorders extra 2012-01-01

The aim of this study was to explore the relationship between cerebrospinal fluid Alzheimer's disease (AD) markers and depression in elderly people. 4 key findings →

Participants: 183 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Drug repositioning and repurposing for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Nature reviews. Neurology 2020-09-16

Drug repositioning and repurposing can enhance traditional drug development efforts and could accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia and mild cognitive impairment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The epidemiology of dementia associated with Parkinson disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the neurological sciences 2009-09-04

Several recent studies have shown that dementia is common in Parkinson's disease (PD), and that in some patients, cognitive impairment occurs even at the time of diagnosis. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed